MARKET

MIST

MIST

Milestone Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.17
+0.12
+1.70%
Opening 12:21 01/15 EST
OPEN
7.05
PREV CLOSE
7.05
HIGH
7.28
LOW
6.93
VOLUME
50.78K
TURNOVER
--
52 WEEK HIGH
23.25
52 WEEK LOW
1.690
MARKET CAP
213.83M
P/E (TTM)
-3.2239
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is Milestone Pharmaceuticals (MIST) A Good Stock To Buy Now?
In this article we will take a look at whether hedge funds think Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]
Insider Monkey · 12/03/2020 03:11
Is Milestone Pharmaceuticals (MIST) A Good Stock To Buy Now?
In this article we will take a look at whether hedge funds think Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]
Insider Monkey · 12/03/2020 03:11
TAICCA and Golden Horse FPP Series Introduce Promising Proposals to International Investors
TAIPEI, Dec. 2, 2020 /CNW/ -- The Taiwan Creative Content Agency (TAICCA) organized an international pitching event for series selected in Golden Horse Film Project Promotion (FPP) on November 19th to potential local and international buyers.
CNW Group · 12/02/2020 11:08
TAICCA and Golden Horse FPP Series Introduce Promising Proposals to International Investors
CNW Group · 12/02/2020 11:08
Government of Canada Creates Task Force on Flood Insurance and Relocation
CNW Group · 11/23/2020 21:44
Government of Canada Creates Task Force on Flood Insurance and Relocation
CNW Group · 11/23/2020 21:44
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:
PR Newswire - PRF · 11/23/2020 12:00
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:
PR Newswire - PRF · 11/23/2020 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MIST. Analyze the recent business situations of Milestone Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MIST stock price target is 13.25 with a high estimate of 18.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 50
Institutional Holdings: 17.69M
% Owned: 59.30%
Shares Outstanding: 29.82M
TypeInstitutionsShares
Increased
6
1.02M
New
19
4.74M
Decreased
3
69.96K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MIST
Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is its short-acting calcium channel blocker. It is developing Etripamil as a nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia (PSVT), as they occur. It is also focused on developing treatments for other indications, such as Atrial Fibrillation and Angina. Etripamil is in Phase-III development for PSVT.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Milestone Pharmaceuticals Inc stock information, including NASDAQ:MIST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MIST stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MIST stock methods without spending real money on the virtual paper trading platform.